UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K/A

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): 
January 16, 2020 (January 10, 2020)

 

ASSERTIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

    001-13111    
    (Commission File Number)    
         
Delaware       94-3229046

(State or other jurisdiction of

incorporation)

      (I.R.S. Employer Identification No.)

 

100 S. Saunders Road, Suite 300, Lake Forest,IL 60045

(Address of principal executive offices, with zip code)

 

(224) 419-7106

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
Common Stock, $0.0001 par value   ASRT   The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Introductory Note

 

On January 13, 2020, Assertio Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) with the Securities and Exchange Commission to report the Registrant’s consummation of the transaction (the “Transaction”) contemplated by the previously announced Asset Purchase Agreement dated December 11, 2019 with Golf Acquiror LLC, an affiliate of Alvogen, Inc.

 

This Amendment No. 1 to the Current Report on Form 8-K amends Item 9.01 of the Original Report to include pro forma financial information. No other changes were made to the Original Report.

 

Item 9.01 Financial Statements and Exhibits

 

(b) Pro Forma Financial Information

 

Attached as Exhibit 99.2 hereto and incorporated by reference is the unaudited pro forma financial information of the Company giving effect to the Transaction.

 

(d) Exhibits

 

Exhibit Number   Description
99.2   Unaudited Pro Forma Financial Information of the Company

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASSERTIO THERAPEUTICS, INC.
   
     
Date: January 16, 2020 By: /s/ Daniel A. Peisert
    Daniel A. Peisert
    Senior Vice President and Chief Financial Officer

 

 

 

Exhibit 99.2 

 

Unaudited Pro Forma Financial Statements

 

Effective as of January 10, 2020, Assertio Therapeutics, Inc. (the “Company”), consummated a transaction (the “Transaction”) contemplated by the previously announced Asset Purchase Agreement dated December 11, 2019 (the “Asset Purchase Agreement”) with Golf Acquiror LLC, an affiliate of Alvogen, Inc. (“Alvogen”). Pursuant to the Asset Purchase Agreement, the Company divested its rights, title and interest in and to Gralise® (gabapentin) (“Gralise”), including certain related assets, to Alvogen. At the closing of the Transaction (the “Closing”), the Company received approximately $78.6 million, including a $75.0 million base purchase price and a preliminary positive inventory adjustment equal to approximately $3.6 million (the “Inventory Amount”). In addition, the Company is entitled to receive 75% of Alvogen’s first $70.0 million of Gralise net sales after the Closing. Alvogen has also assumed, pursuant to the terms of the Asset Purchase Agreement, certain contracts, liabilities and obligations of the Company relating to Gralise, including those related to manufacturing and supply, post-market commitments and clinical development costs. The Inventory Amount is subject to customary post-Closing adjustments which are not expected to be material.

 

In connection with the execution of the Asset Purchase Agreement, the Company, certain subsidiaries of the Company, certain noteholders and Deerfield Private Design Fund III, L.P., as collateral agent (“Deerfield”), entered into a Sixth Amendment (the “Deerfield Amendment”) to the Note Purchase Agreement, dated as of March 12, 2015 (the “Purchase Agreement”), among the Company, the noteholders party thereto and Deerfield. The Deerfield Amendment, among other things, provides that a portion of the purchase price shall be used to prepay $60.5 million principal amount of the outstanding notes issued under the Purchase Agreement.

 

The unaudited pro forma financial statements have been derived from and should be read in conjunction with the historical financial statements and the related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 11, 2019 (the “2018 Form 10-K”) and the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2019 filed with the SEC on November 7, 2019 (the “2019 Form 10-Q”). The unaudited pro forma financial statements may differ materially from the future financial position or results of operations of the Company due to a number of factors described in “Risk Factors” under Item 1A of Part II of the 2019 Form 10-Q.

 

The unaudited pro forma condensed consolidated balance sheet as of September 30, 2019 assumes that the Transaction was completed on September 30, 2019. The unaudited pro forma condensed consolidated statement of operations for the year ended December 31, 2018 and nine months ended September 30, 2019 give effect to the Transaction as if it had been completed as of January 1, 2018. The unaudited pro forma financial information is presented for illustrative purposes only and is not necessarily indicative of the Company’s actual results of operations or financial condition had the Transaction been completed on the dates described above, nor is it necessarily indicative of the Company’s results of operations in future periods or the future financial position of the assets and operations. The financial information should be read in conjunction with the accompanying notes to the unaudited pro forma financial information.

 

The pro forma financial information presented reflects events directly attributable to the Transaction and certain assumptions the Company believes are reasonable. The pro forma adjustments are based on currently available information and certain estimates and assumptions. Therefore, actual adjustments may differ from the pro forma adjustments. However, management believes the pro forma assumptions provide a reasonable basis for presenting significant effects of the Transaction as contemplated and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma financial statements.

 

 1 

 

 

ASSERTIO THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF SEPTEMBER 30, 2019

(in thousands)

 

    Assertio
Therapeutics, Inc.
Historical 
    Pro Forma
Adjustments (i) 
         Pro Forma  
ASSETS                    
Current assets:                    
Cash and cash equivalents   54,181    15,664    (a)    69,845 
Accounts receivable, net   43,427              43,427 
Inventories, net   3,314    (2,979)   (b)    335 
Prepaid and other current assets   23,480    (1,708)   (b)    21,772 
Total current assets   124,402    10,977         135,379 
Property and equipment, net   3,873              3,873 
Intangible assets, net   615,768              615,768 
Investments   7,244              7,244 
Other long-term assets   5,579              5,579 
Total assets   756,866    10,977         767,843 
LIABILITIES AND SHAREHOLDERS EQUITY                    
Current liabilities:                    
Accounts payable   22,700              22,700 
Accrued rebates, returns and discounts   60,979              60,979 
Accrued liabilities   33,270    (7,082)   (g)    26,188 
Current portion of Senior Notes   80,000    (39,000)   (c)    41,000 
Interest payable   6,687    (1,868)   (c)    4,819 
Other current liabilities   2,096              2,096 
Total current liabilities   205,732    (47,950)        157,782 
Contingent consideration liability   981              981 
Senior Notes   94,661    (18,902)   (c)    75,759 
Convertible Notes   190,923              190,923 
Other long-term liabilities   16,135              16,135 
Total liabilities   508,432    (66,852)        441,580 
Commitments and contingencies                    
Shareholders equity:                    
Common stock   8              8 
Additional paid-in capital   455,601              455,601 
Accumulated deficit   (207,175)   77,829    (d)    (129,346)
Accumulated other comprehensive loss   -              - 
Total shareholders equity   248,434    77,829         326,263 
Total liabilities and shareholders' equity   756,866    10,977         767,843 

 

See accompanying notes to unaudited pro forma condensed consolidated financial information.

 

 

 

 

ASSERTIO THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019

(in thousands, except per share amounts)

 

   Assertio
Therapeutics, Inc.
Historical
   Pro Forma
Adjustments (i)
       Pro Forma 
Revenues:                    
Product sales, net   79,889    (46,008)   (e)    33,881 
Commercialization agreement, net   89,163              89,163 
Royalties and milestones   1,226              1,226 
Total revenues   170,278    (46,008)        124,270 
Costs and expenses:                    
Cost of sales (excluding amortization of intangible assets)   6,942    (3,233)   (e)    3,709 
Research and development expenses   4,531    (143)   (e)    4,388 
Selling, general and administrative expenses   85,917    (3,739)   (e)    82,178 
Amortization of intangible assets   76,331              76,331 
Total costs and expenses   173,721    (7,115)        166,606 
Loss from operations   (3,443)   (38,893)        (42,336)
Other (expense) income:                    
Gain on debt extinguishment   26,385              26,385 
Interest expense   (45,268)   6,787    (f)    (38,481)
Other (expense) income, net   (2,613)             (2,613)
Total other expense   (21,496)   6,787         (14,709)
Net loss before income taxes   (24,939)   (32,106)        (57,045)
Income tax benefit   364    7,082    (g)    7,446 
Net loss   (24,575)   (25,024)        (49,599)
                     
Basic net loss per share   (0.36)             (0.74)
Diluted net loss per share   (0.36)             (0.74)
Shares used in computing basic   67,332              67,332 
Shares used in computing diluted   67,332              67,332 

 

See accompanying notes to unaudited pro forma condensed consolidated financial information.  

 

 

 

 

ASSERTIO THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED  DECEMBER 31, 2018

(in thousands, except per share amounts)

 

   Assertio
Therapeutics, Inc.
Historical
   Pro Forma Adjustments (i)       Pro Forma 
Revenues:                    
Product sales, net   129,966    (58,077)   (e)    71,889 
Commercialization agreement, net   155,743              155,743 
Royalties and milestones   26,061              26,061 
Total revenues   311,770    (58,077)        253,693 
Costs and expenses:                    
Cost of sales (excluding amortization of intangible assets)   18,476    (4,320)   (e)    14,156 
Research and development expenses   8,042    (140)   (e)    7,902 
Selling, general and administrative expenses   119,218    (5,417)   (e)    113,801 
Amortization of intangible assets   101,774              101,774 
Restructuring charges   20,601              20,601 
Total costs and expenses   268,111    (9,877)        258,234 
Income (loss) from operations   43,659    (48,200)        (4,541)
Other (expense) income:                    
Litigation settlement   62,000              62,000 
Interest and other income   1,197              1,197 
Interest expense   (68,881)   8,015    (f)    (60,866)
Total other (expense) income   (5,684)   8,015         2,331 
Net income (loss) before income taxes   37,975    (40,185)        (2,210)
Income tax expense   (1,067)   313    (h)    (754)
Net income (loss)   36,908              (2,964)
                     
Basic net income (loss) per share   0.58              (0.05)
Diluted net income (loss) per share   0.57              (0.05)
 Shares used in computing basic   63,794              63,794 
 Shares used in computing diluted   64,208              64,208 

 

See accompanying notes to unaudited pro forma condensed consolidated financial information.

 

 

 

 

Description of Transaction

 

On January 10, 2020 the Company divested its rights, title and interest in and to Gralise, including certain related assets, to Alvogen. At Closing, the Company received approximately $78.6 million, which included $75.0 million in base purchase price and approximately $3.6 million in inventory amounts.  In addition, the Company is entitled to receive 75% of Alvogen’s first $70.0 million of Gralise net sales after the Closing.

 

Per the Deerfield Amendment, a portion of the base purchase price proceeds from Alvogen was used to prepay $60.5 million principal amount of the outstanding notes issued under the Purchase Agreement.

 

Pro forma adjustments


(a)Represents adjustments to reflect proceeds of $75.0 million in base purchase price and approximately $3.0 million in Gralise inventory amounts as of September 30, 2019, less $60.5 million prepayment of the principal amount of the outstanding notes and $1.8 million in prepayment premium pursuant to the Deerfield Amendment.

 

(b)Represents adjustments to eliminate Gralise trade and samples inventory.

 

(c)Represents adjustments to eliminate Senior Notes liabilities pursuant to prepayment of $60.5 million in principal amount of the outstanding notes, net of proportional adjustment to the unamortized debt discount, unamortized debt issuance costs and accrued interest payable.

 

(d)Represents the gain arising from the Transaction based on impact from pro forma adjustments described above that would have been recorded if we had completed the Transaction on September 30, 2019. This estimated gain has not been reflected in the pro forma condensed consolidated statement of operations as it is considered to be nonrecurring in nature.

 

(e)Represents adjustments to eliminate the direct operating results attributable to Gralise as if the divestiture occurred on January 1, 2018. Adjustments to product sales, cost of sales, research and development, and selling, general and administrative expenses include amounts that are directly related to Gralise.

 

(f)Represents adjustments to eliminate interest expense associated with the Company's Senior Notes pursuant to payment of $60.5 million in principal amount of the outstanding notes as if the prepayment occurred on January 1, 2018.

 

(g)Represents adjustments to the estimated income tax benefit (provision) and tax payable for the impact of the pro forma adjustments on the forecasted effective tax rate, including changes in the forecasted valuation allowance and discrete tax amounts recorded for the nine months ended September 30, 2019.

 

(h)Represents adjustments to the tax expense for the impact of the pro forma adjustments on the computation of the income tax provision, including the indirect effects on the related valuation allowance.

 

(i)The pro forma adjustments do not include:
i.Adjustments to eliminate certain Gralise related assets and liabilities that were not transferred to Alvogen as part of the Transaction and are the responsibility of the Company to settle,
ii.Adjustments for sales proceeds the Company is entitled to receive for 75% of Alvogen’s first $70.0 million of Gralise net sales after the Closing Date,
iii.Adjustments for allocations of indirect operating costs or anticipated savings due to costs that may be reduced or eliminated, and
iv.Adjustments to cash consideration to give effect to any potential post-closing adjustments under the terms of the Asset Purchase Agreement.